The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review.

cancer chemoradiotherapy gastrointestinal toxicities gut microbiome radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 May 2021
Historique:
received: 30 03 2021
revised: 06 05 2021
accepted: 10 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Gastrointestinal (GI) toxicities are common adverse effects of pelvic radiotherapy (RT). Several recent studies revealed that toxicity of RT is associated with dysbiosis of the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed, and ScienceDirect, with search terms "microbiome and/or microbiota" and "radiotherapy (RT) and/or chemoradiation therapy (CRT)" and "cancer", and the relevant literature were selected for use in this article. Eight prospective cohort studies were selected for review with a total of 311 participants with a range of 15-134 participants within these studies. The selected studies were conducted in patients with gynaecological ( Gut microbiome profiles are associated with GI toxicities and have the potential to predict RT/CRT-induced toxicities and quality of life (QoL) in patients undergoing those treatments. Further robust randomized controlled trials (RCTs) are required to elucidate the effect of gut microbiome profiles on RT-related adverse effects and responses to RT.

Sections du résumé

BACKGROUND BACKGROUND
Gastrointestinal (GI) toxicities are common adverse effects of pelvic radiotherapy (RT). Several recent studies revealed that toxicity of RT is associated with dysbiosis of the gut microbiome.
METHOD METHODS
A literature search was conducted in electronic databases Medline, PubMed, and ScienceDirect, with search terms "microbiome and/or microbiota" and "radiotherapy (RT) and/or chemoradiation therapy (CRT)" and "cancer", and the relevant literature were selected for use in this article.
RESULTS RESULTS
Eight prospective cohort studies were selected for review with a total of 311 participants with a range of 15-134 participants within these studies. The selected studies were conducted in patients with gynaecological (
CONCLUSION CONCLUSIONS
Gut microbiome profiles are associated with GI toxicities and have the potential to predict RT/CRT-induced toxicities and quality of life (QoL) in patients undergoing those treatments. Further robust randomized controlled trials (RCTs) are required to elucidate the effect of gut microbiome profiles on RT-related adverse effects and responses to RT.

Identifiants

pubmed: 34068216
pii: cancers13102353
doi: 10.3390/cancers13102353
pmc: PMC8153110
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Bioinformatics. 2016 Sep 1;32(17):2618-25
pubmed: 27197815
J Cancer Res Clin Oncol. 2019 Jan;145(1):49-63
pubmed: 30542789
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
Front Microbiol. 2016 Apr 20;7:459
pubmed: 27148170
World J Gastroenterol. 2018 Dec 14;24(46):5223-5233
pubmed: 30581271
J Cell Mol Med. 2019 May;23(5):3747-3756
pubmed: 30908851
PLoS One. 2020 Mar 2;15(3):e0229204
pubmed: 32119675
Life Sci. 2019 Sep 15;233:116680
pubmed: 31344431
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):163-171
pubmed: 31987960
Curr Opin Oncol. 2015 May;27(3):159-64
pubmed: 25774860
Nutr Today. 2016 Jul-Aug;51(4):167-174
pubmed: 27795585
PLoS One. 2013 Dec 18;8(12):e82659
pubmed: 24367534
Genome Med. 2019 Oct 9;11(1):61
pubmed: 31597568
J Immunother Cancer. 2019 Jul 23;7(1):193
pubmed: 31337439
FEBS Lett. 2014 Nov 17;588(22):4223-33
pubmed: 25307765
Adv Med. 2020 Feb 7;2020:6375876
pubmed: 32090133
Am J Gastroenterol. 2008 Jul;103(7):1754-61
pubmed: 18564125
Thorac Cancer. 2021 Jan;12(1):66-78
pubmed: 33111503
Neurobiol Pain. 2020 Jan 29;7:100045
pubmed: 32072077
Acta Endocrinol (Buchar). 2016 Apr-Jun;12(2):206-214
pubmed: 31149088
Clin Microbiol Rev. 2010 Oct;23(4):713-39
pubmed: 20930071
Radiother Oncol. 2020 Feb;143:12-18
pubmed: 32044171
Psychosomatics. 2009 Sep-Oct;50(5):440-7
pubmed: 19855028
Bioinformatics. 2015 Aug 1;31(15):2461-8
pubmed: 25819674
Curr Opin Nephrol Hypertens. 2017 Jan;26(1):1-8
pubmed: 27798455
Future Oncol. 2014 Dec;10(15):2329-44
pubmed: 25525843
Sci Rep. 2016 Aug 03;6:30751
pubmed: 27485780
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Medicine (Baltimore). 2020 Sep 11;99(37):e21788
pubmed: 32925716
Cancer Lett. 2019 Jun 28;452:144-151
pubmed: 30905818
Appl Environ Microbiol. 2016 Jul 29;82(16):5039-48
pubmed: 27342554
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):736-746
pubmed: 32315676
Obesity (Silver Spring). 2010 Jan;18(1):190-5
pubmed: 19498350
Int J Gynecol Cancer. 2017 Sep;27(7):1550-1559
pubmed: 28590950
Gastroenterology. 2020 May;158(6):1524-1528
pubmed: 31930986
mBio. 2018 Jul 31;9(4):
pubmed: 30065092
Nat Commun. 2019 Oct 25;10(1):4881
pubmed: 31653850
Sleep Med. 2020 Aug;72:93-108
pubmed: 32559717
Gut. 2006 Feb;55(2):205-11
pubmed: 16188921
Front Oncol. 2016 Feb 10;6:13
pubmed: 26904500
Radiother Oncol. 2014 Jul;112(1):140-4
pubmed: 24833561
Complement Ther Med. 2007 Dec;15(4):228-37
pubmed: 18054724
Life Sci. 2020 Aug 1;254:117754
pubmed: 32389833
EBioMedicine. 2020 Jan;51:102590
pubmed: 31901868
Cancers (Basel). 2020 Aug 31;12(9):
pubmed: 32878124
Commun Biol. 2021 Feb 22;4(1):237
pubmed: 33619320
Clin Cancer Res. 2019 Nov 1;25(21):6487-6500
pubmed: 31345839
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Radiat Oncol. 2021 Jan 13;16(1):9
pubmed: 33436010
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Behav Pharmacol. 2019 Apr;30(2 and 3-Spec Issue):187-200
pubmed: 30844962
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365
pubmed: 28270698
Carcinogenesis. 2014 Feb;35(2):249-55
pubmed: 24302613
Exerc Sport Sci Rev. 2019 Apr;47(2):75-85
pubmed: 30883471
P R Health Sci J. 2019 Jun;38(2):81-86
pubmed: 31260550
J Dent Res. 2006 Aug;85(8):690-700
pubmed: 16861284
Gut. 2018 Jan;67(1):97-107
pubmed: 28438965
Gut. 2020 Oct;69(10):1867-1876
pubmed: 32759302
PLoS One. 2015 May 08;10(5):e0126312
pubmed: 25955845
J Thorac Oncol. 2019 Aug;14(8):1378-1389
pubmed: 31026576
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567

Auteurs

Byeongsang Oh (B)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Thomas Eade (T)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Gillian Lamoury (G)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Susan Carroll (S)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Marita Morgia (M)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.

Andrew Kneebone (A)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

George Hruby (G)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Mark Stevens (M)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.

Frances Boyle (F)

The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Stephen Clarke (S)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Brian Corless (B)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.

Mark Molloy (M)

Bowel Cancer and Biomarker Laboratory, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2065, Australia.

David Rosenthal (D)

Harvard Medical School, Boston, MA 02215, USA.

Michael Back (M)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
The Mater Hospital, Sydney, NSW 2060, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.

Classifications MeSH